Broadfin Capital’s Exagen XGN Stock Holding History

Broadfin Capital’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-311,284	Closed	-$4.82M	–	47
2019 Q3	$4.82M	Buy	+311,284	New	+$5.02M	0.89%	28

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Broadfin Capital's XGN Position: Q4 2019 in Review

Broadfin Capital sold out of Exagen (XGN) in Q4 2019, closing a stake of 311,284 shares — an estimated $4.82M sold.

Broadfin Capital first reported a position in XGN in Q3 2019 and held it in 1 quarter. The position peaked at $4.82M in Q3 2019. 36 funds tracked by Wall St. Rank hold XGN as of Q4 2019.

Broadfin Capital reported no remaining Exagen position as of Q4 2019 after selling out during the quarter.
Broadfin Capital sold 311,284 Exagen shares in Q4 2019, an estimated $4.82M.
Broadfin Capital first reported a position in Exagen in Q3 2019 and held it in 1 quarter.
Broadfin Capital's Exagen position peaked at $4.82M in Q3 2019.
36 funds tracked by Wall St. Rank held Exagen as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.